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dose CsA. We agree that these renal lesions of interstitial tion, and a decrease in oxygen demand in the medulla [3].
In addition, adenosine also appears to decrease sodiumfibrosis and tubular atrophy are not necessarily followed
by a progressive loss of renal function after a treatment chloride transport in the thick ascending limb of Henle’s
of one year with CsA. However, the results of long-term loop [3] as well as to increase blood flow to the medulla
studies [refs. 69, 70, 85], that is, an increase of interstitial by dilating the vasa recta (abstract; Clin Res 36:627A,
fibrosis as a function of time, clearly indicate the progres- 1988). Adenosine administration results in a significant
sive nature of CsA-induced nephrotoxicity. increase in medullary PO2 (in conjunction with a de-
Ponticelli and colleagues state that CsA nephropathy crease in cortical PO2) [5].
is reversible after drug withdrawal. As we discussed, the Thus, I would offer an alternative interpretation to
functional impairment was reversible after withdrawal the observations by Erley et al. While adenosine unques-
of CsA, complete in six studies, but only partial in seven tionably decreases renal function (renal blood flow, glo-
studies. However, follow-up studies after withdrawal merular filtration rate, and reabsorption), this may con-
clearly show that a subgroup of patients still has in- stitute a protective effect, preserving renal viability and
creased levels of serum creatinine 20 to 24 months after assuring better renal function after ischemic insult to the
cessation of the drug [refs. 57 and 64]. Moreover, the kidneys. Oliguria is a sign of a decreased renal function
morphological changes induced by CsA are not revers- which may be interpreted as “acute renal success” [6].
ible and progress in a function of time. Perhaps we should postpone using adenosine antagonists
We agree that short-term treatment of CsA according in the clinical setting in question until further studies on
to the dosage guidelines has an acceptable risk of pro- high-risk patients reveal the truth.
gressive renal dysfunction, but we strongly fear that long-
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1976To the Editor: The interesting and impeccably de-
signed study by Erley et al convincingly demonstrates
the role of adenosine and adenosine receptors in renal Reply from the authors
function [1]. However, their tentative conclusion, that
To the Editor: We express concern about the interpre-adenosine antagonists would be effective in preventing
tation and “tentative conclusion” of our paper, in whichrenal impairment following radiocontrast-medium ad-
we recommend the use of adenosine receptor antagonistsministration is not justified by the study and may be
in the prevention of renal functional impairment followingwrong. There is a fundamental difference between renal
administration of radiocontrast media, especially in thefunction and renal viability. Adenosine constricts pre-
presence of additional risk factors [1]. Instead, Gelmanglomerular vessels and dilates post-glomerular vessels
and Sadovnikoff present an alternative interpretation of(via A1 and A2 receptors, respectively) [2–5]. This re-
our findings, based upon an assumption of a “fundamentalsults in a significant decrease in intra-glomerular pres-
difference between renal function and renal viability.”sure and a decrease in glomerular filtration rate. This is
The authors argue that a decline in renal function wouldexactly what the authors observed. However, a decrease
represent an “acute renal success,” as termed by Thurauin glomerular filtration would result in a decrease in solute
and Boylan [2]. In this context, however, we feel thatdelivery to the tubulae, a decrease in the tubular reabsorp-
this represents an incomplete interpretation of the renal
response to tubular injury, since Thurau and Boylan
described “acute renal success” as a conservation of sys- 1999 by the International Society of Nephrology
